371
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Examining and interpreting responsiveness of the Diabetes Medication Satisfaction measure

, , &
Pages 309-316 | Published online: 08 Oct 2009
 

Abstract

Objective: Treatment satisfaction (TS) is an important patient reported outcome (PRO) in diabetes as it is correlated with outcomes necessary for optimal treatment (e.g., compliance, self-management behaviour). The objective of this study was to examine the responsiveness of the DiabMedSat, a disease-specific PRO measure, assessing Overall, Burden, Efficacy and Symptom TS.

Methods: The DiabMedSat was included in an open label, observational study of the safety and efficacy of biphasic insulin aspart 30 (NovoMix 30) in routine practice with type 2 diabetes. Responsiveness analyses, examining both internal and external responsiveness, were conducted and minimally important differences (MID) assessed.

Results: In 18,817 patients, all TS scores significantly improved after 26 weeks of treatment (p<0.001). The effect sizes for these changes were above 0.5 indicating that the ability to detect change was moderate-to-large in size. Significant differences were found for all TS scores comparing patients who met their HbA1c goal, who improved but did not meet goal and who did not improve (p<0.01), and for patients who experienced a minor hypoglycaemic event and those who did not (p<0.001). DiabMedSat scores were able to detect changes in patients’ own global rating of satisfaction (MID ranging from 5.3 to 11.7) and in physician-rated satisfaction with patients’ HbA1c improvement (MID ranging from 5.3 to 10.2).

Conclusions: In the context of an observational study, the DiabMedSat has been shown to be highly responsive to change and can be considered as an acceptable PRO measure for TS in diabetes.

Declaration of funding: This study was funded by Novo Nordisk.

Declaration of financial/other relationships: M.B. and D.M.B. have disclosed that they are advisors/paid consultants to Novo Nordisk. T.C. and J.H.K. have disclosed that they are employees of Novo Nordisk. All authors participated in the conceptualisation, data interpretation and manuscript preparation.

The peer reviewers of this paper have disclosed that they have no relevant financial relationships.

Acknowledgment:

The authors have disclosed that they had no outside editorial assistance in preparing this manuscript.

Notes

* NovoMix 30 is a registered trademark of Novo Nordisk A/S, Bagsværd, Denmark.

* NovoMix 30 is a registered trademark of Novo Nordisk A/S, Bagsværd, Denmark.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.